Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Surgical Idiopathic Intracranial Hypertension Treatment Trial
NCT03501966 · Jaeb Center for Health Research · PHASE3 · terminated · last registry update 2022-06-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low enrollment” | – | Registry record, Jaeb Center for Health Research |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-04-27Also stopped (terminated): The University of Texas Health Science Center, Houston, Acetazolamide + Placebo (NCT02466074)
- 2023-03-01Results posted on the registry: The University of Texas Health Science Center, Houston, Acetazolamide + Placebo (NCT02466074)
- 2023-02-15Results posted on the registry: CrystalGenomics, Inc., CG100649 + Celecoxib (NCT01765296)
- 2023-02-09Results posted on the registry: CrystalGenomics, Inc., CG100649 + Celecoxib (NCT01341405)
- 2023-02-01Phase 3 first posted: Beijing Tiantan Hospital, Acetazolamide-based medical therapy (NCT05707442)
- 2023-01-12Results posted on the registry: University of Vermont Medical Center, a drug against CA1 (NCT03846024)
- 2023-01-12Also stopped (terminated): University of Vermont Medical Center, a drug against CA1 (NCT03846024)
- 2022-12-12Also stopped (withdrawn): West Virginia University, Sufentanil (NCT04464512)
- 2022-11-03Phase 3 first posted: Arthritis Innovation Corporation, F14 + 0.25 % Bupivacaine HCl (NCT05603832)
- 2021-12-14Also stopped (withdrawn): University of Miami, Acetazolamide (NCT04351061)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision